Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer.

However, when the data from the 161 patients with EGFR-activating mutations were analysed, DFS was better with erlotinib (46.4 vs 28.5 mo; HR: 0.61, 95%CI: 0.384-0.981; P = 0.039), but this did not reach statistical significance due to the hierarchical analysis established in the study design.

also in 111,027 other papers